Cingolani Gino, Panella Andrea, Perrone Maria Grazia, Vitale Paola, Di Mauro Giuseppe, Fortuna Cosimo G, Armen Roger S, Ferorelli Savina, Smith William L, Scilimati Antonio
Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Institute of Biomembranes and Bioenergetics, National Research Council, Via Amendola 165/A, 70125 Bari, Italy.
Department of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Via E. Orabona 4, 70125 Bari, Italy.
Eur J Med Chem. 2017 Sep 29;138:661-668. doi: 10.1016/j.ejmech.2017.06.045. Epub 2017 Jun 24.
The diarylisoxazole molecular scaffold is found in several NSAIDs, especially those with high selectivity for COX-1. Here, we have determined the structural basis for COX-1 binding to two diarylisoxazoles: mofezolac, which is polar and ionizable, and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6) that has very low polarity. X-ray analysis of the crystal structures of COX-1 bound to mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole allowed the identification of specific binding determinants within the enzyme active site, relevant to generate structure/activity relationships for diarylisoxazole NSAIDs.
二芳基异恶唑分子骨架存在于多种非甾体抗炎药中,尤其是那些对COX-1具有高选择性的药物。在此,我们确定了COX-1与两种二芳基异恶唑结合的结构基础:极性且可离子化的莫非佐辛,以及极性极低的3-(5-氯呋喃-2-基)-5-甲基-4-苯基异恶唑(P6)。对与莫非佐辛和3-(5-氯呋喃-2-基)-5-甲基-4-苯基异恶唑结合的COX-1晶体结构进行X射线分析,使得能够鉴定出酶活性位点内与生成二芳基异恶唑非甾体抗炎药结构/活性关系相关的特异性结合决定因素。